TP53 overexpression
|
SCCHN
|
TP53 overexpression
|
SCCHN
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials
|
TP53 overexpression
|
GIST
|
TP53 overexpression
|
GIST
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
TP53 overexpression
|
Mantle Cell Lymphoma
|
TP53 overexpression
|
Mantle Cell Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
TP53 overexpression
|
Endometrial Cancer
|
TP53 overexpression
|
Endometrial Cancer
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|